A new study from scientists at La Jolla Institute for Immunology (LJI) has given researchers a guide to neutralizing the deadly Lassa virus (LSV) using a trio of rare antibodies isolated from survivors of Lassa virus infection. The LJI scientists showed exactly how a cocktail of three human antibodies can block viral infection, which they say may prove valuable in upcoming clinical trials for Lassa therapies. “We now know where these three therapeutic antibodies act and how exactly they act,” said Kathryn Hastie, PhD, an LJI instructor and director of the Antibody Discovery Center at LJI.
